Nordic Nanovector: Results From Preclinical Studies of Betalutin® in Combination with Rituximab to Be Presented at ASH

Nordic Nanovector announces that a poster describing the therapeutic effect of combined treatment with Betalutin and rituximab in a preclinical...

Nordic Nanovector: Safety Review Committee Supports Dose Escalation in Lymrit 37-01 Trial

Nordic Nanovector announces that the independent Safety Review Committee for the ongoing Lymrit 37-01 clinical trial of Betalutin has given...

Nordic Nanovector Announces Changes to the Board of Directors and Notice of Extraordinary General Meeting

Renee Tannenbaum has informed Nordic Nanovector ASA ("Company") of her resignation from the board of directors for personal reasons. The...